Riskpilot← Back to searchSign inGet full accessZerapeutics AB
ABActiveOrg 5593535015Erik Dahlbergsgatan 11 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
+6% vs 2023
Equity ratio
99.7%
Financial strength
Net profit 2024
SEK -104K
+5% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -135K | +6% |
| Net profit | SEK -104K | +5% |
| Total assets | SEK 2M | -7% |
| Equity | SEK 2M | -5% |
| Employees | 0 | — |
Legal name
Zerapeutics AB
Org number
5593535015
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 december 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Fletcher, Lorna May
Company purpose
Föremålet för bolagets verksamhet är att bedriva utveckling och kommersialisering, inklusive försäljning och licensering av intellektuell egendom, av molekyler som påverkar proteiner tillhörande BET boromodomän familjen för behandling av melanom och andra likartade sjukdomar samt bedriva därmed förenlig verksamhet.
Address
Erik Dahlbergsgatan 11 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Staff expenses | — | — | — |
| EBITDA | −80 | −143 | −135 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −80 | −143 | −135 |
| Net financials | — | 33 | 31 |
| Profit before tax | −80 | −110 | −104 |
| Tax | −0 | −0 | −0 |
| Net profit | −80 | −110 | −104 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 2 179 | 2 107 | 1 960 |
| Equity | 2 169 | 2 059 | 1 954 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 10 | 49 | 5 |
| Total debt | 10 | 49 | 5 |
EBITDA margin
-13500000.0%
This company
15.8%
Market median
-85443138% vs market
20222024
Equity ratio
99.7%
This company
38.2%
Market median
+161% vs market
20222024
Return on equity
-5.3%
This company
18.4%
Market median
-129% vs market
20222024
Net profit margin
-10400000.0%
This company
8.1%
Market median
-128395162% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-12-01 – 2022-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Zerapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lorna May Fletcher | Chairman | 0 companies |
| Jonas Andrej Nilsson | Board of Directors | 0 companies |
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Lars Thomas Brimert | Board of Directors | 0 companies |
| Björn Ulrik Walse | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |